Index -
P/E -
EPS (ttm) -16.62
Insider Own 25.59%
Shs Outstand 22.81M
Perf Week -13.66%
Market Cap 40.37M
Forward P/E -
EPS next Y -2.52
Insider Trans 0.61%
Shs Float 16.98M
Perf Month 2.31%
Income -49.41M
PEG -
EPS next Q -1.21
Inst Own 15.89%
Short Float 9.49%
Perf Quarter -0.56%
Sales 82.62M
P/S 0.49
EPS this Y 43.86%
Inst Trans -11.35%
Short Ratio 6.22
Perf Half Y -14.49%
Book/sh 0.79
P/B 2.24
EPS next Y 47.11%
ROA -24.93%
Short Interest 1.61M
Perf Year -69.74%
Cash/sh 3.34
P/C 0.53
EPS next 5Y 25.50%
ROE -223.65%
52W Range 1.24 - 6.15
Perf YTD -41.20%
Dividend Est. -
P/FCF -
EPS past 5Y 22.28%
ROI -49.01%
52W High -71.22%
Beta 1.81
Dividend TTM -
Quick Ratio 1.24
Sales past 5Y 26.66%
Gross Margin 66.89%
52W Low 42.74%
ATR (14) 0.14
Dividend Ex-Date -
Current Ratio 1.37
EPS Y/Y TTM -16.74%
Oper. Margin -115.12%
RSI (14) 37.92
Volatility 8.02% 6.79%
Employees 186
Debt/Eq 4.95
Sales Y/Y TTM 31.68%
Profit Margin -59.80%
Recom 1.00
Target Price 13.67
Option/Short Yes / Yes
LT Debt/Eq 4.64
EPS Q/Q 79.94%
Payout -
Rel Volume 1.76
Prev Close 1.85
Sales Surprise 0.99%
EPS Surprise 40.33%
Sales Q/Q -14.32%
Earnings Aug 13 AMC
Avg Volume 259.03K
Price 1.77
SMA20 -9.11%
SMA50 -9.99%
SMA200 -13.08%
Trades
Volume 456,618
Change -4.32%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-15-24 Resumed
ROTH MKM
Buy
$10
Aug-04-22 Initiated
Ladenburg Thalmann
Buy
$6
Oct-02-20 Initiated
The Benchmark Company
Buy
$9
Dec-18-19 Initiated
B. Riley FBR
Buy
$9
Feb-28-18 Initiated
B. Riley FBR, Inc.
Buy
$10
Jul-11-17 Initiated
Rodman & Renshaw
Buy
$11
Mar-22-17 Initiated
JMP Securities
Mkt Outperform
Oct-03-16 Initiated
ROTH Capital
Buy
$9
Sep-04-24 08:30AM
08:15AM
08:00AM
Sep-03-24 08:30AM
Sep-02-24 08:50AM
05:15PM
Loading…
Aug-13-24 05:15PM
04:16PM
(Associated Press Finance)
04:05PM
Aug-12-24 04:01PM
08:30AM
Aug-09-24 04:05PM
Aug-06-24 04:01PM
Jul-25-24 08:30AM
07:30AM
Jul-15-24 08:50AM
08:00AM
Loading…
08:00AM
Jul-11-24 04:05PM
Jul-05-24 04:05PM
Jul-02-24 08:00AM
07:00AM
Jun-24-24 07:30AM
Jun-21-24 04:01PM
Jun-20-24 08:30AM
08:00AM
Jun-17-24 08:30AM
May-16-24 08:30AM
08:00AM
May-15-24 10:53PM
04:32PM
(Associated Press Finance)
04:15PM
04:01PM
Loading…
04:01PM
08:30AM
May-14-24 11:14AM
08:30AM
May-13-24 04:01PM
08:30AM
May-10-24 08:30AM
May-07-24 08:30AM
May-02-24 04:01PM
May-01-24 04:01PM
Apr-29-24 08:00PM
08:00AM
Apr-25-24 08:30AM
Apr-24-24 07:30AM
Apr-11-24 12:24PM
Mar-28-24 10:53PM
04:05PM
09:00AM
Mar-25-24 08:30AM
Mar-22-24 08:30AM
Mar-21-24 04:01PM
Mar-18-24 04:05PM
08:30AM
08:00AM
Mar-15-24 08:30AM
08:15AM
Mar-13-24 08:30AM
Mar-12-24 08:30AM
Mar-11-24 04:05PM
08:30AM
08:00AM
Mar-07-24 07:30AM
Mar-04-24 08:30AM
Feb-22-24 08:30AM
Feb-02-24 02:40PM
Jan-29-24 08:00AM
Jan-11-24 08:30AM
08:15AM
08:00AM
Jan-09-24 05:02PM
(GuruFocus.com) -6.19%
-8.49%
Jan-05-24 09:15AM
08:30AM
Jan-04-24 08:30AM
Jan-03-24 04:01PM
Jan-02-24 04:05PM
08:30AM
Dec-29-23 08:20AM
Dec-11-23 08:30AM
Dec-06-23 08:30AM
08:30AM
08:00AM
Dec-05-23 08:30AM
Dec-01-23 08:30AM
Nov-16-23 11:18PM
Nov-14-23 04:29PM
(Associated Press Finance)
04:10PM
04:05PM
04:01PM
Nov-13-23 05:00PM
04:05PM
Nov-10-23 08:15AM
Nov-09-23 05:05PM
Nov-07-23 04:01PM
Nov-02-23 03:00PM
09:28AM
Oct-31-23 09:15AM
08:30AM
Oct-30-23 02:15PM
Oct-26-23 12:30PM
09:00AM
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROSENWALD LINDSAY A MD President, CEO & Chairman Jul 11 '24 Buy 7.48 5,000 37,418 127,500 Jul 15 04:05 PM Jin David Chief Financial Officer Jul 10 '24 Buy 7.50 500 3,750 500 Jul 12 08:42 AM ROSENWALD LINDSAY A MD President, CEO & Chairman Jul 09 '24 Buy 7.39 5,000 36,971 122,500 Jul 11 08:00 AM ROSENWALD LINDSAY A MD President, CEO & Chairman Jul 08 '24 Buy 7.35 5,000 36,764 117,500 Jul 10 08:30 AM ROSENWALD LINDSAY A MD President, CEO & Chairman Jun 28 '24 Buy 1.64 20,000 32,724 2,893,905 Jul 01 08:40 AM ROSENWALD LINDSAY A MD President, CEO & Chairman May 16 '24 Buy 1.76 10,000 17,589 2,873,905 May 20 05:00 PM Klein Dov Director May 20 '24 Sale 1.89 10,000 18,900 53,400 May 20 04:56 PM ROSENWALD LINDSAY A MD President, CEO & Chairman Jan 05 '24 Buy 2.38 50,000 118,770 2,863,905 Jan 09 08:15 AM ROSENWALD LINDSAY A MD President, CEO & Chairman Nov 14 '23 Buy 1.70 1,567,515 2,664,776 2,597,440 Nov 16 05:50 PM WEISS MICHAEL S See Remarks Nov 14 '23 Buy 1.70 147,058 249,999 1,130,520 Nov 16 05:46 PM ROSENWALD LINDSAY A MD President, CEO & Chairman Sep 26 '23 Buy 0.28 100,000 28,330 15,449,091 Sep 27 08:20 AM Fortress Biotech, Inc. 10% Owner Sep 08 '23 Buy 0.72 418,410 301,255 1,032,390 Sep 12 09:02 AM
Index -
P/E -
EPS (ttm) -0.01
Insider Own 52.71%
Shs Outstand 13.32M
Perf Week -10.17%
Market Cap 97.02M
Forward P/E -
EPS next Y -0.21
Insider Trans 0.52%
Shs Float 9.80M
Perf Month -4.88%
Income 0.84M
PEG -
EPS next Q -0.17
Inst Own 11.39%
Short Float 1.30%
Perf Quarter 0.00%
Sales 77.68M
P/S 1.25
EPS this Y -408.57%
Inst Trans 5.95%
Short Ratio 1.69
Perf Half Y 34.87%
Book/sh 0.56
P/B 8.29
EPS next Y 80.71%
ROA 1.25%
Short Interest 0.13M
Perf Year 86.45%
Cash/sh 1.15
P/C 4.06
EPS next 5Y -
ROE 14.92%
52W Range 1.92 - 8.11
Perf YTD -18.75%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI 2.72%
52W High -42.29%
Beta 0.92
Dividend TTM -
Quick Ratio 1.08
Sales past 5Y 23.37%
Gross Margin 66.79%
52W Low 143.75%
ATR (14) 0.36
Dividend Ex-Date -
Current Ratio 1.36
EPS Y/Y TTM 104.72%
Oper. Margin 2.73%
RSI (14) 44.40
Volatility 6.81% 8.23%
Employees 58
Debt/Eq 2.02
Sales Y/Y TTM 26.38%
Profit Margin 1.09%
Recom 1.00
Target Price 9.10
Option/Short No / Yes
LT Debt/Eq 1.75
EPS Q/Q 63.81%
Payout -
Rel Volume 0.35
Prev Close 4.70
Sales Surprise 6.96%
EPS Surprise -18.63%
Sales Q/Q -13.49%
Earnings Aug 12 AMC
Avg Volume 75.27K
Price 4.68
SMA20 -1.72%
SMA50 -9.27%
SMA200 -0.07%
Trades
Volume 26,332
Change -0.43%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-22-24 Initiated
Rodman & Renshaw
Buy
$9
Jun-28-24 Resumed
ROTH MKM
Buy
$11
Dec-07-21 Initiated
B. Riley Securities
Buy
$14
Sep-04-24 08:15AM
Aug-13-24 04:05PM
Aug-12-24 05:10PM
04:01PM
Aug-06-24 04:01PM
04:15PM
Loading…
Jul-17-24 04:15PM
Jul-11-24 04:05PM
May-15-24 04:15PM
04:01PM
May-14-24 03:07AM
May-13-24 08:55PM
04:01PM
May-07-24 08:30AM
May-01-24 04:01PM
Apr-29-24 09:00AM
08:30AM
Loading…
Apr-25-24 08:30AM
Mar-28-24 04:05PM
(GlobeNewswire) -5.40%
-10.05%
Mar-25-24 07:01PM
(GuruFocus.com) -11.52%
+26.37%
Mar-22-24 06:01AM
(Thomson Reuters StreetEvents) -13.61%
Mar-21-24 09:53PM
04:01PM
Mar-19-24 08:49AM
Mar-18-24 08:30AM
Mar-15-24 08:30AM
Mar-13-24 08:30AM
Mar-11-24 08:30AM
Feb-26-24 11:35AM
Jan-05-24 08:30AM
Jan-02-24 04:05PM
(GlobeNewswire) -5.73%
-8.29%
Dec-27-23 08:50AM
08:09AM
Loading…
Dec-13-23 08:09AM
Dec-07-23 09:16AM
Dec-06-23 08:00AM
Nov-30-23 12:00PM
Nov-29-23 08:50AM
Nov-14-23 04:10PM
Nov-12-23 09:36AM
Nov-07-23 04:01PM
(GlobeNewswire) +5.54%
+9.62%
Nov-01-23 08:00AM
Oct-31-23 08:30AM
Oct-20-23 08:30AM
Sep-09-23 01:04AM
Sep-07-23 11:45AM
Sep-06-23 08:00AM
Aug-14-23 04:01PM
Aug-08-23 06:05PM
04:01PM
Aug-03-23 05:35PM
Aug-02-23 04:01PM
Jul-19-23 08:30AM
Jul-11-23 08:30AM
Jul-04-23 07:34AM
Jul-03-23 08:00AM
Jun-14-23 12:03PM
Jun-13-23 12:11PM
08:30AM
May-22-23 05:15PM
04:01PM
May-19-23 04:01PM
May-15-23 04:01PM
May-11-23 04:01PM
May-04-23 09:00AM
Apr-19-23 02:22PM
Apr-01-23 09:41PM
Mar-30-23 04:10PM
(GlobeNewswire) +10.34%
+11.17%
Mar-29-23 05:15PM
04:01PM
Mar-28-23 05:35PM
Mar-22-23 09:00AM
Mar-16-23 08:30AM
Mar-07-23 08:30AM
Jan-20-23 04:01PM
(GlobeNewswire) -7.57%
+6.03%
Jan-10-23 08:30AM
Dec-20-22 10:02AM
08:30AM
Dec-05-22 04:05PM
Nov-13-22 07:38AM
Nov-10-22 05:25PM
04:01PM
Nov-03-22 08:52AM
Oct-04-22 08:30AM
Aug-30-22 08:30AM
Aug-12-22 06:14AM
Aug-09-22 05:55PM
04:01PM
Aug-04-22 10:00AM
Aug-03-22 08:00AM
Jul-18-22 07:05AM
May-24-22 08:30AM
May-23-22 08:30AM
May-16-22 01:20PM
08:00AM
May-10-22 04:01PM
(GlobeNewswire) -5.35%
-7.34%
May-03-22 04:15PM
Apr-15-22 09:55AM
Apr-04-22 08:30AM
Apr-01-22 08:30AM
Mar-23-22 04:01PM
Mar-18-22 01:15PM
Mar-17-22 08:30AM
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Benesch Joseph CFO Aug 01 '24 Sale 5.47 9,324 51,002 47,331 Aug 01 04:18 PM Benesch Joseph CFO Jul 23 '24 Sale 5.40 4,055 21,897 56,655 Jul 23 04:01 PM ROSENWALD LINDSAY A MD Director Mar 25 '24 Buy 3.04 10,000 30,400 144,245 Mar 27 07:00 AM Maraoui Claude President & CEO Mar 22 '24 Buy 3.48 10,000 34,790 2,163,430 Mar 25 04:03 PM Smith Justin Adam Director Mar 22 '24 Buy 3.47 30,000 104,100 134,717 Mar 25 04:02 PM ROSENWALD LINDSAY A MD Director Mar 22 '24 Buy 3.40 20,000 68,000 134,245 Mar 25 04:01 PM Benesch Joseph Interim CFO Feb 22 '24 Sale 3.75 2,450 9,188 60,710 Feb 23 05:54 PM Paley Jeffrey Director Nov 07 '23 Sale 3.48 2,245 7,813 114,472 Dec 08 05:01 PM Paley Jeffrey Director Nov 08 '23 Sale 3.76 255 959 114,217 Dec 08 05:01 PM Paley Jeffrey Director Nov 28 '23 Sale 5.22 1,745 9,109 70,727 Nov 29 04:42 PM Smith Justin Adam Director Oct 13 '23 Buy 2.98 33,000 98,340 104,717 Oct 17 04:01 PM Paley Jeffrey Director Oct 06 '23 Buy 2.98 15,000 44,700 72,472 Oct 10 04:41 PM Paley Jeffrey Director Sep 21 '23 Buy 2.97 30,000 89,100 57,472 Sep 25 04:01 PM
Index -
P/E -
EPS (ttm) -7.41
Insider Own 7.38%
Shs Outstand 1.43M
Perf Week 12.30%
Market Cap 4.05M
Forward P/E -
EPS next Y -3.14
Insider Trans 0.00%
Shs Float 1.33M
Perf Month 20.94%
Income -10.36M
PEG -
EPS next Q -0.94
Inst Own 8.13%
Short Float 3.54%
Perf Quarter -21.39%
Sales 0.00M
P/S -
EPS this Y 91.35%
Inst Trans -
Short Ratio 1.03
Perf Half Y -78.36%
Book/sh 4.00
P/B 0.71
EPS next Y 50.63%
ROA -311.39%
Short Interest 0.05M
Perf Year -94.96%
Cash/sh 3.44
P/C 0.82
EPS next 5Y -
ROE -1037.72%
52W Range 2.25 - 64.27
Perf YTD -76.56%
Dividend Est. -
P/FCF -
EPS past 5Y 50.07%
ROI -217.46%
52W High -95.60%
Beta -0.21
Dividend TTM -
Quick Ratio 4.30
Sales past 5Y 0.00%
Gross Margin -
52W Low 25.78%
ATR (14) 0.24
Dividend Ex-Date -
Current Ratio 4.30
EPS Y/Y TTM 94.83%
Oper. Margin 0.00%
RSI (14) 52.15
Volatility 6.05% 8.31%
Employees 3
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 12.00
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q 83.40%
Payout -
Rel Volume 0.27
Prev Close 2.80
Sales Surprise -
EPS Surprise -512.38%
Sales Q/Q -
Earnings Aug 09 AMC
Avg Volume 45.72K
Price 2.83
SMA20 6.68%
SMA50 -5.28%
SMA200 -64.44%
Trades
Volume 12,125
Change 1.07%
Sep-03-24 08:30AM
Aug-13-24 04:05PM
Aug-09-24 08:53PM
04:05PM
Jun-20-24 08:30AM
08:30AM
Loading…
May-16-24 08:30AM
May-15-24 09:55PM
08:30AM
Apr-29-24 08:00AM
Apr-24-24 07:30AM
Mar-25-24 08:30AM
Mar-19-24 06:53AM
Mar-18-24 04:05PM
Mar-15-24 08:15AM
Mar-11-24 08:00AM
08:30AM
Loading…
Feb-22-24 08:30AM
Jan-16-24 08:40AM
Jan-11-24 08:00AM
Jan-05-24 09:15AM
Jan-04-24 08:30AM
Jan-02-24 08:30AM
Dec-01-23 08:30AM
Nov-29-23 08:05AM
Nov-13-23 04:05PM
Nov-02-23 03:00PM
Oct-31-23 09:15AM
Sep-05-23 08:30AM
Aug-14-23 04:01PM
Aug-10-23 04:15PM
Aug-01-23 08:30AM
08:30AM
Loading…
Jul-27-23 08:30AM
Jul-25-23 08:30AM
May-15-23 04:01PM
May-12-23 08:30AM
Apr-27-23 08:30AM
Apr-17-23 04:01PM
(GlobeNewswire) +5.50%
-6.09%
Mar-30-23 04:10PM
04:01PM
Mar-08-23 04:01PM
Mar-02-23 08:00AM
Jan-31-23 01:30PM
01:09PM
Jan-27-23 11:58AM
Nov-10-22 04:10PM
(GlobeNewswire) +12.23%
-10.43%
Nov-08-22 12:26PM
08:30AM
Oct-12-22 10:25AM
Oct-11-22 02:15PM
Oct-06-22 11:00PM
(GlobeNewswire) -25.74%
-57.71%
Oct-03-22 08:00AM
Sep-23-22 08:51AM
Sep-22-22 04:25PM
Mar-31-22 07:30AM
Feb-16-22 08:20AM
Feb-15-22 10:00PM
07:05AM
Dec-15-21 02:15PM
12:00PM
Dec-12-21 08:00PM
Nov-29-21 08:00AM
Nov-17-21 09:30AM
Nov-12-21 10:40AM
09:20AM
Nov-09-21 09:30PM
(GlobeNewswire) -8.14%
-18.35%
Oct-25-21 07:00AM
Aug-26-21 11:04AM
Jun-21-21 08:04AM
Jun-14-21 08:42AM
07:44AM
07:00AM
Apr-26-21 08:09AM
Apr-23-21 11:36PM
09:43AM
08:41AM
Apr-22-21 10:59AM
Apr-21-21 10:34PM
09:38AM
Apr-19-21 10:09PM
06:26AM
Apr-16-21 11:25PM
Apr-14-21 10:34PM
Apr-13-21 11:30PM
03:09PM
02:30PM
09:33AM
06:30AM
Apr-12-21 01:36AM
Jan-11-21 11:32PM
Jan-06-21 09:23AM
Dec-18-20 08:00AM
08:00AM
Dec-17-20 04:27PM
07:00AM
Nov-13-20 05:28AM
Oct-28-20 07:45PM
Oct-23-20 10:00PM
Oct-14-20 08:58PM
10:10AM
Oct-13-20 01:29PM
Oct-12-20 01:35PM
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Davidow Robert L 10% Owner Dec 11 '23 Sale 0.14 353,000 49,600 22,000 Dec 13 04:02 PM Davidow Robert L 10% Owner Dec 11 '23 Sale 0.14 264,000 36,960 681,000 Dec 13 04:02 PM ROSENWALD LINDSAY A MD Director Sep 08 '23 Buy 0.72 348,675 251,046 354,318 Sep 12 09:03 AM Fortress Biotech, Inc. 10% Owner Sep 08 '23 Buy 0.72 418,410 301,255 1,032,390 Sep 12 09:02 AM
Index -
P/E -
EPS (ttm) -2.98
Insider Own 10.03%
Shs Outstand 37.23M
Perf Week -7.14%
Market Cap 10.46M
Forward P/E -
EPS next Y -3.93
Insider Trans 0.00%
Shs Float 33.50M
Perf Month -7.87%
Income -32.06M
PEG -
EPS next Q -
Inst Own 2.24%
Short Float 4.83%
Perf Quarter 81.29%
Sales 0.00M
P/S -
EPS this Y 45.83%
Inst Trans -39.48%
Short Ratio 0.06
Perf Half Y -79.78%
Book/sh -0.24
P/B -
EPS next Y -20.92%
ROA -170.53%
Short Interest 1.62M
Perf Year -89.59%
Cash/sh 0.11
P/C 2.45
EPS next 5Y -
ROE -1191.31%
52W Range 0.13 - 2.91
Perf YTD -79.19%
Dividend Est. -
P/FCF -
EPS past 5Y 18.87%
ROI -
52W High -90.36%
Beta 1.93
Dividend TTM -
Quick Ratio 0.46
Sales past 5Y 0.00%
Gross Margin -
52W Low 119.36%
ATR (14) 0.04
Dividend Ex-Date -
Current Ratio 0.46
EPS Y/Y TTM 68.60%
Oper. Margin 0.00%
RSI (14) 38.88
Volatility 10.60% 11.12%
Employees 80
Debt/Eq -
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 10.00
Option/Short No / Yes
LT Debt/Eq -
EPS Q/Q 82.25%
Payout -
Rel Volume 0.02
Prev Close 0.28
Sales Surprise -
EPS Surprise 47.13%
Sales Q/Q -
Earnings May 10
Avg Volume 27.22M
Price 0.28
SMA20 -16.15%
SMA50 -23.31%
SMA200 -64.87%
Trades
Volume 437,930
Change -0.93%
Date
Action
Analyst
Rating Change
Price Target Change
May-18-21 Initiated
BTIG Research
Buy
$11
Oct-02-20 Initiated
B. Riley FBR
Buy
$9
Nov-20-19 Initiated
Cantor Fitzgerald
Overweight
$7
Aug-13-19 Initiated
H.C. Wainwright
Buy
$7
Jun-21-19 Initiated
Cantor Fitzgerald
Overweight
$7
Dec-21-17 Initiated
Oppenheimer
Outperform
$18
Jun-28-24 08:00AM
Jun-21-24 04:01PM
Jun-20-24 05:26PM
08:00AM
07:28AM
10:22AM
Loading…
Jun-18-24 10:22AM
07:37AM
07:30AM
Jun-17-24 01:28PM
01:03PM
12:07PM
08:30AM
May-22-24 08:04AM
07:23AM
May-16-24 10:53AM
04:01PM
Loading…
May-02-24 04:01PM
(GlobeNewswire) +12.65%
+8.46%
Apr-30-24 06:03AM
Apr-29-24 08:00PM
Mar-28-24 04:05PM
09:00AM
Mar-11-24 04:05PM
(GlobeNewswire) -7.20%
-8.62%
Mar-07-24 07:30AM
Jan-11-24 08:30AM
Dec-11-23 08:30AM
Nov-14-23 04:05PM
Nov-02-23 09:28AM
Oct-30-23 02:15PM
Oct-26-23 12:30PM
09:00AM
Sep-07-23 08:15AM
08:00AM
Loading…
Aug-16-23 08:00AM
Aug-14-23 04:05PM
(GlobeNewswire) -11.04%
-5.71%
04:01PM
Aug-03-23 08:00AM
Jul-31-23 08:30AM
Jul-06-23 08:00AM
Jun-15-23 04:01PM
(GlobeNewswire) +10.76%
+9.44%
Jun-13-23 01:49PM
Jun-12-23 09:55AM
08:00AM
May-26-23 09:55AM
May-18-23 08:03AM
May-15-23 04:01PM
May-12-23 04:05PM
May-11-23 04:03PM
Apr-03-23 12:15PM
Mar-30-23 04:10PM
Mar-29-23 04:15PM
Mar-28-23 08:30AM
Jan-17-23 08:15AM
Dec-19-22 08:30AM
Nov-14-22 04:05PM
Oct-27-22 08:00AM
Oct-06-22 08:30AM
Sep-08-22 08:00AM
Sep-02-22 09:55AM
Aug-11-22 04:05PM
Jul-27-22 08:00AM
Jul-17-22 08:21AM
Jun-22-22 08:00AM
Jun-13-22 08:00AM
May-19-22 03:23PM
08:45AM
May-12-22 04:05PM
10:38AM
May-03-22 08:00AM
Apr-25-22 08:00AM
Apr-21-22 08:30AM
Apr-13-22 10:00AM
Apr-04-22 08:00AM
Apr-01-22 08:30AM
Mar-23-22 04:05PM
(GlobeNewswire) -9.71%
+22.58%
Mar-10-22 08:30AM
Mar-09-22 08:00AM
Mar-08-22 09:00AM
Feb-15-22 07:30AM
Feb-08-22 08:30AM
Feb-07-22 09:11AM
Jan-25-22 07:10AM
Jan-24-22 05:00PM
Jan-07-22 02:05PM
Jan-05-22 08:30AM
Dec-16-21 08:30AM
Dec-13-21 09:00AM
Dec-09-21 08:30AM
Dec-06-21 07:30AM
Nov-12-21 08:05AM
Nov-10-21 08:00AM
Nov-09-21 09:02AM
Nov-04-21 09:24AM
Nov-01-21 10:19AM
08:30AM
Oct-06-21 10:28AM
Oct-04-21 09:57AM
Sep-30-21 08:30AM
Sep-28-21 08:30AM
Sep-24-21 06:10AM
Sep-09-21 08:30AM
Aug-16-21 04:01PM
Aug-13-21 10:03AM
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Worcester, MA.
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite